Treatment of Inflammatory Bowel Disease with Biologics

148

Molander et al. [^67

]

CD,17; UC, 30

Prospective observational (83% with concomitant IMM)

CD: 29% (1.1 year)

Nil identified

Age, gender, duration of disease, location, disease activity at discontinuation

100% (CD)

IBDU: 5

UC: 35% (1.1 year)

90% (UC)

Armuzzi et al. [^55

]

CD: 65

Retrospective (% of with concomitant IMM not reported)Retrospective (71% with concomitant IMM)

CD: 49% [median 1.1(0.3–6.2) years]

Absence of mucosal healing

Not reported

• 
  

UC: 31

UC: 41% [median 1.3(0.3–2.5) years]

High CRP

Casanova et al. [^60

]

CD: 717UC: 338

24% (1 year)

Adalimumab (rather than infliximab)

Not available

75%

38% (2 years)46% (3 years)

Elective discontinuation of anti-TNF-

α therapy

56% (5 years)

Discontinuation of anti-TNF-

α due to adverse

eventsYounger age at discontinuationNo maintenance IMM

Authors

Number of participants (

n)

Study design

Relapse rate

Significant predictors of relapse

Predictors evaluated but not found to be significant

Recapture rate

Table 10.1

(continued)

H.H. Shim and C.H. Seow